CEL-SCI Home Page
preload preload

Press Releases

December 8, 2014
NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites

December 2, 2014
NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

November 3, 2014
NEW STORY CEL-SCI Enrolls 22 Patients during October in Its Phase III Immunotherapy Head and Neck Cancer Trial

October 24, 2014
NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million

October 21, 2014
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering

October 3, 2014
NEW STORY CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial

September 29, 2014
NEW STORY CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

September 10, 2014
NEW STORY University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial

September 3, 2014
NEW STORY CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial

August 19, 2014
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada

August 8, 2014
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results

July 30, 2014
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial

July 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

July 11, 2014
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY